HC Wainwright Forecasts RenovoRx’s Q2 Earnings (NASDAQ:RNXT)

RenovoRx, Inc. (NASDAQ:RNXT) – HC Wainwright cut their Q2 2025 earnings per share (EPS) estimates for RenovoRx in a report issued on Monday, May 19th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.08) for the quarter, down from their prior estimate of ($0.07). HC Wainwright has a “Buy” rating and a $3.00 price target on the stock. The consensus estimate for RenovoRx’s current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for RenovoRx’s Q3 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.32) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.29) EPS and FY2027 earnings at $0.08 EPS.

Separately, Ascendiant Capital Markets increased their target price on shares of RenovoRx from $9.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, April 28th.

RenovoRx Stock Performance

NASDAQ RNXT opened at $1.22 on Wednesday. The firm has a market cap of $44.62 million, a price-to-earnings ratio of -2.14 and a beta of 1.12. The firm has a 50 day simple moving average of $0.98 and a 200-day simple moving average of $1.14. RenovoRx has a one year low of $0.75 and a one year high of $1.69.

RenovoRx (NASDAQ:RNXT) last posted its earnings results on Thursday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). The business had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.23 million.

Institutional Investors Weigh In On RenovoRx

Several institutional investors have recently modified their holdings of RNXT. HighTower Advisors LLC acquired a new position in RenovoRx during the first quarter worth $40,000. Citadel Advisors LLC acquired a new stake in RenovoRx in the fourth quarter valued at $49,000. Renaissance Technologies LLC acquired a new position in shares of RenovoRx during the 4th quarter worth $84,000. Chicago Partners Investment Group LLC purchased a new position in RenovoRx during the 1st quarter valued at about $97,000. Finally, Corsair Capital Management L.P. acquired a new position in RenovoRx during the first quarter worth about $186,000. Hedge funds and other institutional investors own 3.10% of the company’s stock.

RenovoRx Company Profile

RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.